DK2961378T3 - Fremgangsmåder til behandlingen af mitochondrisk sygdom - Google Patents
Fremgangsmåder til behandlingen af mitochondrisk sygdom Download PDFInfo
- Publication number
- DK2961378T3 DK2961378T3 DK14757000T DK14757000T DK2961378T3 DK 2961378 T3 DK2961378 T3 DK 2961378T3 DK 14757000 T DK14757000 T DK 14757000T DK 14757000 T DK14757000 T DK 14757000T DK 2961378 T3 DK2961378 T3 DK 2961378T3
- Authority
- DK
- Denmark
- Prior art keywords
- mitochondric
- disease
- treating
- methods
- treating mitochondric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/207—Pigmentation disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361771642P | 2013-03-01 | 2013-03-01 | |
US201361771534P | 2013-03-01 | 2013-03-01 | |
PCT/US2014/019645 WO2014134562A1 (en) | 2013-03-01 | 2014-02-28 | Methods for the treatment of mitochondrial disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2961378T3 true DK2961378T3 (da) | 2019-11-25 |
Family
ID=51428871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14757000T DK2961378T3 (da) | 2013-03-01 | 2014-02-28 | Fremgangsmåder til behandlingen af mitochondrisk sygdom |
Country Status (10)
Country | Link |
---|---|
US (3) | US10793597B2 (da) |
EP (2) | EP2961378B1 (da) |
JP (2) | JP6839490B2 (da) |
CN (5) | CN117752766A (da) |
CA (1) | CA2916884C (da) |
DK (1) | DK2961378T3 (da) |
ES (1) | ES2755134T3 (da) |
HK (1) | HK1219653A1 (da) |
HU (1) | HUE046596T2 (da) |
WO (1) | WO2014134562A1 (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107312066A (zh) * | 2011-12-09 | 2017-11-03 | 康德生物医疗技术公司 | 芳香族阳离子肽及其用途 |
EP2961420B1 (en) | 2013-03-01 | 2019-09-11 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
US10047395B2 (en) | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
EP3501532A3 (en) * | 2014-05-28 | 2019-07-17 | Stealth BioTherapeutics Corp | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof |
JP2019523260A (ja) | 2016-04-11 | 2019-08-22 | カーノット, エルエルシー | キラルペプチド |
CN117205298A (zh) * | 2016-05-19 | 2023-12-12 | 康德生物医疗有限公司 | 用于预防和治疗线粒体肌病的组合物和方法 |
WO2018187400A1 (en) | 2017-04-05 | 2018-10-11 | Stealth Biotherapeutics Corp. | Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2 |
US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
EP3864417A1 (en) * | 2018-10-10 | 2021-08-18 | Helsingin Yliopisto | Biomarkers for mitochondrial diseases and related methods |
WO2020214518A1 (en) * | 2019-04-18 | 2020-10-22 | Arcuate Therapeutics, Inc. | Methods of treating renal conditions using peptides that improve mitochondrial function |
US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
CA2457391A1 (en) | 2001-08-06 | 2003-02-20 | Vanderbilt University | Device and methods for detecting the response of a plurality of cells to at least one analyte of interest |
BRPI0105509B8 (pt) | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
DK2656854T3 (da) * | 2003-02-04 | 2015-07-06 | Cornell Res Foundation Inc | Anvendelser af et aromatisk-kationisk peptid |
CN101440124B (zh) * | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
CA2514071A1 (en) | 2003-02-10 | 2004-08-19 | Autogen Research Pty Ltd | Therapeutic molecules |
US20070026090A1 (en) * | 2003-09-05 | 2007-02-01 | Oren Tirosh | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
CA2851972C (en) * | 2004-01-23 | 2015-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
US8500720B2 (en) | 2005-05-09 | 2013-08-06 | Medtronic, Inc | Method and apparatus for treatment of cardiac disorders |
US20070265216A1 (en) | 2005-10-05 | 2007-11-15 | Gross Richard W | Enhanced medical treatment in diabetic cardiomyopathy |
US20090298848A1 (en) | 2006-04-18 | 2009-12-03 | Cortendo Invest Ab, | Methods and Compositions for Treating Barth Syndrome, Cardiomyopathy, Mitochondrial Diseases and Other Conditions |
EP2150117A4 (en) * | 2007-05-02 | 2011-10-05 | Mclean Hospital Corp | METHOD AND COMPOSITIONS FOR MITOCHONDRIAL SPARE THERAPY |
US20080318909A1 (en) | 2007-06-14 | 2008-12-25 | Sparagna Genevieve C | Use Of Linoleic Compounds Against Heart Failure |
WO2008156654A2 (en) * | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Cytoskeleton modulators for treating metabolic disorders |
DK2262520T3 (da) * | 2008-02-26 | 2017-08-07 | Univ Cornell | Sammensætninger til forebyggelse og behandling af nyreskader |
WO2009149307A2 (en) | 2008-06-04 | 2009-12-10 | San Diego State University Research Foundation | Compositions and methods for restoring mitochondrial electron transfer function |
US8999940B2 (en) | 2008-08-07 | 2015-04-07 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
EP3563862B1 (en) * | 2009-03-20 | 2021-05-05 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries |
US20120122957A1 (en) * | 2009-04-17 | 2012-05-17 | The Salk Institute For Biological Studies | Regulation of aging by modulation of mitochondrial function |
US20120046363A1 (en) | 2009-05-11 | 2012-02-23 | University Of Maryland, Baltimore | Docosahexaenoic acid for the treatment of heart failure |
CN102647994A (zh) | 2009-08-12 | 2012-08-22 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
CA2772094C (en) * | 2009-08-24 | 2018-04-03 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
EP2944317A1 (en) * | 2009-10-05 | 2015-11-18 | Cornell University | Methods for the prevention or treatment of heart failure |
WO2011082324A1 (en) | 2009-12-31 | 2011-07-07 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
EP2519232A1 (en) * | 2009-12-31 | 2012-11-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
US8719939B2 (en) | 2009-12-31 | 2014-05-06 | Mcafee, Inc. | Malware detection via reputation system |
JP4643749B1 (ja) | 2010-02-03 | 2011-03-02 | 昭和電工株式会社 | 表面被覆サーメット部材の耐酸化膜形成用の処理液 |
EP3332795A1 (en) | 2010-02-26 | 2018-06-13 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
EP3560508A1 (en) | 2010-03-15 | 2019-10-30 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
EP2942354A1 (en) | 2010-05-03 | 2015-11-11 | Stealth Peptides International, Inc. | Aromatic-Cationic Peptides and Uses of Same |
WO2012009171A2 (en) * | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
AU2011285619B2 (en) * | 2010-08-06 | 2016-12-01 | Ptc Therapeutics, Inc. | Treatment of mitochondrial diseases with naphthoquinones |
WO2012019032A1 (en) * | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
US9241933B2 (en) * | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
WO2012129427A2 (en) * | 2011-03-24 | 2012-09-27 | Cornell University | Aromatic-cationic peptides and uses of same |
JP6157481B2 (ja) | 2011-09-29 | 2017-07-05 | メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ | 芳香族陽イオン性ペプチドおよびその使用方法 |
CA2852454A1 (en) * | 2011-10-17 | 2013-04-25 | Cornell University | Aromatic-cationic peptides and uses of same |
KR20190077124A (ko) | 2011-10-21 | 2019-07-02 | 스템제닉스 인코포레이티드 | 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자 |
JP2015509500A (ja) * | 2012-02-22 | 2015-03-30 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 眼疾患を予防または治療するための方法および組成物 |
CN104203262A (zh) * | 2012-02-23 | 2014-12-10 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
US20150266946A1 (en) * | 2012-10-09 | 2015-09-24 | President And Fellows Of Harvard College | Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function |
BR112015009072A2 (pt) | 2012-10-22 | 2017-07-04 | Henry Ford Health Systems | métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma |
EP2961420B1 (en) | 2013-03-01 | 2019-09-11 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
US10047395B2 (en) | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
-
2014
- 2014-02-28 EP EP14757000.6A patent/EP2961378B1/en active Active
- 2014-02-28 DK DK14757000T patent/DK2961378T3/da active
- 2014-02-28 CN CN202311795418.1A patent/CN117752766A/zh active Pending
- 2014-02-28 CA CA2916884A patent/CA2916884C/en active Active
- 2014-02-28 CN CN201910589605.1A patent/CN110339339A/zh active Pending
- 2014-02-28 ES ES14757000T patent/ES2755134T3/es active Active
- 2014-02-28 CN CN202310407669.1A patent/CN116474071A/zh active Pending
- 2014-02-28 WO PCT/US2014/019645 patent/WO2014134562A1/en active Application Filing
- 2014-02-28 JP JP2015560380A patent/JP6839490B2/ja active Active
- 2014-02-28 HU HUE14757000A patent/HUE046596T2/hu unknown
- 2014-02-28 EP EP19199765.9A patent/EP3673913A1/en active Pending
- 2014-02-28 US US14/771,411 patent/US10793597B2/en active Active
- 2014-02-28 CN CN202310408404.3A patent/CN116440247A/zh active Pending
- 2014-02-28 CN CN201480022764.9A patent/CN105517533A/zh active Pending
-
2016
- 2016-06-30 HK HK16107656.2A patent/HK1219653A1/zh unknown
-
2019
- 2019-07-19 JP JP2019133638A patent/JP2019214580A/ja active Pending
-
2020
- 2020-07-15 US US16/930,028 patent/US20200407396A1/en not_active Abandoned
-
2022
- 2022-10-11 US US17/963,697 patent/US20230279051A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019214580A (ja) | 2019-12-19 |
CN116474071A (zh) | 2023-07-25 |
JP6839490B2 (ja) | 2021-03-10 |
CA2916884A1 (en) | 2014-09-04 |
US20200407396A1 (en) | 2020-12-31 |
CA2916884C (en) | 2021-02-09 |
EP2961378A4 (en) | 2016-08-17 |
US20160002293A1 (en) | 2016-01-07 |
CN117752766A (zh) | 2024-03-26 |
ES2755134T3 (es) | 2020-04-21 |
CN105517533A (zh) | 2016-04-20 |
CN116440247A (zh) | 2023-07-18 |
HUE046596T2 (hu) | 2020-03-30 |
WO2014134562A9 (en) | 2015-10-08 |
CN110339339A (zh) | 2019-10-18 |
EP2961378B1 (en) | 2019-10-23 |
HK1219653A1 (zh) | 2017-04-13 |
JP2016511260A (ja) | 2016-04-14 |
WO2014134562A1 (en) | 2014-09-04 |
EP3673913A1 (en) | 2020-07-01 |
EP2961378A1 (en) | 2016-01-06 |
US20230279051A1 (en) | 2023-09-07 |
US10793597B2 (en) | 2020-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2968208T3 (da) | Behandling af kataplexi | |
DK3030323T3 (da) | Kdm1a-inhibitorer til behandlingen af sygdom | |
DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
DK2983787T3 (da) | Fremgangsmåde til behandling af posttraumatisk stresssygdom | |
DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
DK2961388T3 (da) | Kombinationer af lægemidler | |
DK3021838T3 (da) | Behandling af fedme | |
DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
DK3626270T3 (da) | Behandling af kardiovaskulære sygdomme | |
DK2986722T3 (da) | Manipulerede phenylalaninammoniak-lyasepolypeptider | |
DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
BR302013003401S1 (pt) | Configuração aplicada em bolsa | |
DK3076786T3 (da) | Fælde | |
DK2992104T3 (da) | Fremgangsmåde til ekspression | |
DK3511004T3 (da) | Kombineret præparat til behandling af cancer | |
BR112015021083A2 (pt) | método | |
DK3014032T3 (da) | Afløb | |
BR112015029076A2 (pt) | método | |
DK2986325T3 (da) | Fremgangsmåder til behandling af forstyrrelser i urinstofcyklus | |
DK3016682T3 (da) | Metoder til behandling af kræft | |
DK3369435T3 (da) | Sammensætning til behandling af inflammatorisk ledsygdom | |
DK2968606T3 (da) | Behandling af autoimmune sygdomme | |
DK2976101T3 (da) | Behandlingsfremgangsmåde |